抗T淋巴细胞单克隆抗体治疗骨髓增生异常综合征

Treatment of Myelodysplastic Syndrome with Monoclonal Anti-Human T Lymphocyte Antibody

用抗T淋巴细胞单克隆抗体SMU3(抗CD3)和SMU8(抗CD8)治疗10例骨髓增生异常综合征(MDS),结果表明:2例明显进步,5例进步,白细胞和血红蛋白显著升高。治疗前CD4^+细胞少,CD8^+细胞多,CD4/CD8比值降低或倒置,HLA-DR抗原高表达,与对照组比较均有显著差异,治疗后T淋巴细胞亚群比例恢复,HLA-DR表达降低。T淋巴细胞各亚群比例失调和功能异常是MDS的诱发因素之一。

Ten patients with myelodysplastic syndrome (MDS) were treated with monoclonal anti -human T lymphocyte antibodies SMU3 (anti - CD3) and SMU8 (anti - CD8) . The results suggested that two patients got a significant progress and five patients turned better. Before treatment the patients had less CD4+cells, more CD8 cells, lower or inverted ratio of CD4/ CD8, higher expression of HLA -DR antigen than normal control and these differences were significant. After treatment T lymphocyte subsets and HLA - DR expression turned normal. T lymphocyte subsets imbalance and abnormal function in patients is one of the factors which induced MDS.